These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31898856)

  • 1. Vesicular monoamine transporter 2 mediates fear behavior in mice.
    Branco RC; Burkett JP; Black CA; Winokur E; Ellsworth W; Dhamsania RK; Lohr KM; Schroeder JP; Weinshenker D; Jovanovic T; Miller GW
    Genes Brain Behav; 2020 Jun; 19(5):e12634. PubMed ID: 31898856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vesicular Monoamine Transporter 2 (VMAT2) Level Regulates MPTP Vulnerability and Clearance of Excess Dopamine in Mouse Striatal Terminals.
    Lohr KM; Chen M; Hoffman CA; McDaniel MJ; Stout KA; Dunn AR; Wang M; Bernstein AI; Miller GW
    Toxicol Sci; 2016 Sep; 153(1):79-88. PubMed ID: 27287315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
    Lohr KM; Stout KA; Dunn AR; Wang M; Salahpour A; Guillot TS; Miller GW
    ACS Chem Neurosci; 2015 May; 6(5):790-9. PubMed ID: 25746685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice.
    Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA
    J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.
    Alter SP; Stout KA; Lohr KM; Taylor TN; Shepherd KR; Wang M; Guillot TS; Miller GW
    Exp Neurol; 2016 Jan; 275 Pt 1(Pt 1):17-24. PubMed ID: 26428905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.
    Caudle WM; Richardson JR; Wang MZ; Taylor TN; Guillot TS; McCormack AL; Colebrooke RE; Di Monte DA; Emson PC; Miller GW
    J Neurosci; 2007 Jul; 27(30):8138-48. PubMed ID: 17652604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems.
    Hall FS; Itokawa K; Schmitt A; Moessner R; Sora I; Lesch KP; Uhl GR
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):146-55. PubMed ID: 23978383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.
    Lohr KM; Bernstein AI; Stout KA; Dunn AR; Lazo CR; Alter SP; Wang M; Li Y; Fan X; Hess EJ; Yi H; Vecchio LM; Goldstein DS; Guillot TS; Salahpour A; Miller GW
    Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9977-82. PubMed ID: 24979780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
    Guillot TS; Shepherd KR; Richardson JR; Wang MZ; Li Y; Emson PC; Miller GW
    J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.
    Taylor TN; Alter SP; Wang M; Goldstein DS; Miller GW
    Neuropharmacology; 2014 Jan; 76 Pt A(0 0):97-105. PubMed ID: 24025942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
    Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
    Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.
    Lohr KM; Miller GW
    Expert Rev Neurother; 2014 Oct; 14(10):1115-7. PubMed ID: 25220836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.
    Cliburn RA; Dunn AR; Stout KA; Hoffman CA; Lohr KM; Bernstein AI; Winokur EJ; Burkett J; Schmitz Y; Caudle WM; Miller GW
    J Chem Neuroanat; 2017 Oct; 83-84():82-90. PubMed ID: 27836486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.
    Zai CC; Tiwari AK; Mazzoco M; de Luca V; Müller DJ; Shaikh SA; Lohoff FW; Freeman N; Voineskos AN; Potkin SG; Lieberman JA; Meltzer HY; Remington G; Kennedy JL
    J Psychiatr Res; 2013 Nov; 47(11):1760-5. PubMed ID: 24018103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion of the vesicular monoamine transporter 1 (vmat1/slc18a1) gene affects dopamine signaling.
    Lohoff FW; Carr GV; Brookshire B; Ferraro TN; Lucki I
    Brain Res; 2019 Jun; 1712():151-157. PubMed ID: 30685272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity.
    Taylor TN; Caudle WM; Shepherd KR; Noorian A; Jackson CR; Iuvone PM; Weinshenker D; Greene JG; Miller GW
    J Neurosci; 2009 Jun; 29(25):8103-13. PubMed ID: 19553450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.
    Narboux-Nême N; Sagné C; Doly S; Diaz SL; Martin CB; Angenard G; Martres MP; Giros B; Hamon M; Lanfumey L; Gaspar P; Mongeau R
    Neuropsychopharmacology; 2011 Nov; 36(12):2538-50. PubMed ID: 21814181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.
    Narendran R; Jedema HP; Lopresti BJ; Mason NS; Himes ML; Bradberry CW
    Biol Psychiatry; 2015 Mar; 77(5):488-92. PubMed ID: 25062684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vesicular monoamine transporter 2 (Vmat2) knockdown elicits anxiety-like behavior in zebrafish.
    Wang Y; Li S; Liu W; Wang F; Hu LF; Zhong ZM; Wang H; Liu CF
    Biochem Biophys Res Commun; 2016 Feb; 470(4):792-7. PubMed ID: 26801555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.